Notably, some RCTs have shown that exenatide, one of the GLP-1 RAs, reduces the intra-abdominal fat volume, adipocytokine concentrations, inflammation, and insulin resistance in obese patients with T2DM31. This evidence concerns the gene GLP1R and Insulin resistance.